Key result
Cytomegalovirus infection was not associated with an increased risk of allograft rejection in heart transplant recipients.
Why the study?
The association between cytomegalovirus infection and allograft rejection after heart transplantation is debated in the era of efficient prophylactic antiviral therapies.
Does cytomegalovirus infection increase the risk of allograft rejection in heart transplant recipients?
Cohort (n=384)
No
Does cytomegalovirus infection increase the risk of allograft rejection in heart transplant recipients?
Answers are grounded in this paper and cite their sources.
In a contemporary cohort of heart transplant recipients, CMV infection was not associated with an increased risk of allograft rejection.
BACKGROUND: Cytomegalovirus (CMV) infection remains a common complication after heart transplantation (HTx). The association between CMV infection and allograft rejection is debated in the era of efficient prophylactic antiviral therapies. METHODS: This single-center cohort study utilized a highly phenotyped database of HTx recipients (2012-2016). The primary endpoint was the analysis of the association between CMV infection (CMV load ≥ 500 IU/mL whole blood) and the risk of allograft rejection (cellular rejection ≥ 1R1B, antibody-mediated rejection ≥ pAMR1). Secondary endpoints included the analysis of a higher CMV load threshold (≥10 000 IU/mL) and different risk periods after PCR positivity. A mixed-effect logistic regression model with a random intercept was applied. Results were adjusted for important risk factors of rejection. RESULTS: Overall, 384 patients were included and 6388 CMV loads and 3,494 endomyocardial biopsies were analyzed. CMV infections ≥ 500 IU/mL were diagnosed on 1223 (19.2%) blood samples from 284 (72.1%) patients and allograft rejections on 246 biopsies (7%) from 149 patients (38.8%). We did not find any association between CMV infection ≥ 500 IU/mL and rejection (univariable: OR 0.94, 95% CI [0.61, 1.45], P = .78, multivariable: OR 0.86, 95% CI [0.55, 1.33], P = .85). These results were consistent when analyzing a higher CMV load threshold and different periods of risk, reinforced by internal validation procedures and a posteriori calculation of the power (primary endpoint: power = 0.82, 95% CI [0.79-0.84]) and reproducible across different clinical scenarios. CONCLUSIONS: CMV infection was not associated with an increased risk of rejection in a contemporary cohort of HTx recipients.
No takes yet. Share an insight, caveat, or question.
Boutolleau et al. (2021) conducted a cohort in Heart transplant recipients (n=384). Cytomegalovirus (CMV) infection (CMV load ≥ 500 IU/mL) vs. No CMV infection or CMV load < 500 IU/mL was evaluated on Risk of allograft rejection (cellular rejection ≥ 1R1B, antibody-mediated rejection ≥ pAMR1) (OR 0.86, 95% CI 0.55-1.33, p=0.85). Cytomegalovirus infection was not associated with an increased risk of allograft rejection in heart transplant recipients.
Synapse has enriched 10 related papers. Consider them for comparative context: